Global Implanted Stent Market Size By Type (Metallic Biomaterials, Polymers Biomaterials), By Application (Coronary Stents, Renal), By Region, And Segment Forecasts, 2023 to 2032

The Global Implanted Stent Market was valued at USD 10.3 billion in 2023 and is projected to reach USD 17.8 billion by 2031, growing at a CAGR of 6.9% during the forecast period from 2023 to 2031. The market is driven by the increasing incidence of cardiovascular diseases, the aging global population, and growing demand for minimally invasive procedures. Technological advancements in bioresorbable stents and drug-eluting stents (DES) are significantly improving patient outcomes, fueling the adoption of implanted stents worldwide.

Drivers:

1. Rising Prevalence of Cardiovascular Disorders:

The increasing global burden of heart-related ailments, including coronary artery disease and peripheral artery disease, is the primary growth catalyst for the implanted stent market.

2. Advancements in Stent Technology:

Continuous innovation in materials and design, such as biodegradable stents and next-gen DES, is enhancing procedural success and long-term efficacy.

3. Growing Preference for Minimally Invasive Surgeries:

The medical community's shift toward non-invasive and minimally invasive cardiac procedures is propelling the use of implanted stents.

Restraints:

1. High Cost of Advanced Stents:

The premium pricing of advanced drug-eluting and bioresorbable stents poses affordability issues, particularly in developing countries.

2. Stringent Regulatory Approvals:

Extended regulatory timelines and approval barriers for new product launches slow down market expansion, especially for emerging players.

Opportunity:

1. Expansion in Emerging Economies:

Rapidly developing healthcare infrastructure and increasing healthcare expenditure in Asia-Pacific and Latin America present substantial growth opportunities.

2. Increasing Adoption of Biodegradable Stents:

The growing focus on temporary scaffolding with long-term vessel restoration is boosting the demand for biodegradable stent technology.

Market by System Type Insights:

Based on system type, the Drug-Eluting Stents (DES) segment dominated the market in 2023, accounting for the largest share due to their high efficacy in reducing restenosis. However, the Bioresorbable Stents segment is expected to grow at the fastest rate during the forecast period, driven by favorable clinical outcomes and ongoing research.

Market by End-Use Insights:

The Hospitals segment held the largest market share in 2023. Hospitals remain the primary end-users owing to the availability of advanced infrastructure, skilled professionals, and a higher volume of percutaneous coronary interventions (PCI). The Ambulatory Surgical Centers (ASCs) segment is projected to grow steadily due to shorter procedure times and lower costs.

Market by Regional Insights:

North America led the global implanted stent market in 2023, supported by a well-established healthcare system, high per capita health spending, and a significant patient population with cardiovascular conditions. Meanwhile, the Asia-Pacific region is projected to witness the fastest CAGR through 2031, fueled by an aging population, lifestyle changes, and healthcare reforms in countries such as China and India.

Competitive Scenario:

Prominent players in the global implanted stent market include Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, BIOTRONIK SE & Co. KG, Terumo Corporation, B. Braun Melsungen AG, MicroPort Scientific Corporation, and Cook Medical. These companies are focusing on product innovations, expanding geographic presence, and securing regulatory approvals to strengthen their market positions.

Scope of Work – Global Implanted Stent Market

Report Metric Details

Market Size (2023) USD 10.3 billion

Projected Market Size (2031) USD 17.8 billion

CAGR (2023-2031) 6.9%

Market Segments By System Type (Bare Metal, DES, Bioresorbable), By End-use (Hospitals, ASCs), By Region

Growth Drivers High CVD prevalence, minimally invasive preference, stent innovations

Opportunities Emerging markets expansion, bioresorbable tech adoption

Key Market Developments:

March 2023: Boston Scientific launched the SYNERGY XD Drug-Eluting Stent in Europe with enhanced deliverability and healing properties.

October 2023: Abbott Laboratories received FDA approval for its next-generation bioresorbable stent, boosting its U.S. presence.

January 2024: Medtronic announced a strategic partnership with a leading Asian healthcare group to introduce DES in regional catheterization labs.

FAQs:

1) What is the current market size of the Global Implanted Stent Market?

The market was valued at USD 10.3 billion in 2023.

2) What is the major growth driver of the Global Im